Publikationen in Zusammenarbeit mit Forschern von Hospital Universitario Puerta de Hierro (11)

2023

  1. Expert recommendations for the use of apremilast in psoriatic arthritis

    Reumatologia Clinica, Vol. 19, Núm. 1, pp. 34-44

2021

  1. Factors associated with long-term retention of treatment with golimumab in rheumatoid arthritis, axial spondyloarthritis, and psoriatic arthritis: an analysis of the Spanish BIOBADASER registry

    Clinical Rheumatology, Vol. 40, Núm. 10, pp. 3979-3988

  2. Role of targeted therapies in rheumatic patients on COVID-19 outcomes: Results from the COVIDSER study

    RMD Open, Vol. 7, Núm. 3

  3. Update of the Position Paper of the Spanish Society of Rheumatology on Biosimilar Drugs

    Reumatologia Clinica, Vol. 17, Núm. 3, pp. 160-169

2020

  1. A cross-disease meta-GWAS identifies four new susceptibility loci shared between systemic sclerosis and Crohn’s disease

    Scientific Reports, Vol. 10, Núm. 1

2019

  1. GWAS for systemic sclerosis identifies multiple risk loci and highlights fibrotic and vasculopathy pathways

    Nature Communications, Vol. 10, Núm. 1

2018

  1. Status of Rheumatology in Spain in 2017: 2.0 Rheumatologists per 100,000 Population

    Reumatologia Clinica

2015

  1. Documento de posicionamiento de la Sociedad Española de Reumatología sobre fármacos biosimilares

    Reumatologia Clinica, Vol. 11, Núm. 5, pp. 269-278

  2. Erratum to "Cardiovascular morbidity and associated risk factors in Spanish patients with chronic inflammatory rheumatic diseases attending rheumatology clinics: Baseline data of the CARMA Project" [Semin Arthritis Rheum 44 (2015) 618-626]

    Seminars in Arthritis and Rheumatism

2012

  1. ¿Qué opinan los residentes de reumatología sobre su formación? Una encuesta de la Comisión Nacional de Reumatología

    Reumatologia Clinica, Vol. 8, Núm. 1, pp. 27-30

2011

  1. No evidence for association between the CCR5/Delta32CCR5 polymorphism and systemic sclerosis

    Clinical and Experimental Rheumatology